Last A$0.09 AUD
Change Today +0.008 / 10.26%
Volume 394.8K
AVH On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 10:32 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

avita medical ltd (AVH) Snapshot

Open
A$0.08
Previous Close
A$0.08
Day High
A$0.09
Day Low
A$0.08
52 Week High
01/28/14 - A$0.14
52 Week Low
12/4/14 - A$0.08
Market Cap
28.0M
Average Volume 10 Days
89.5K
EPS TTM
A$-0.02
Shares Outstanding
325.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVITA MEDICAL LTD (AVH)

Related News

No related news articles were found.

avita medical ltd (AVH) Related Businessweek News

No Related Businessweek News Found

avita medical ltd (AVH) Details

Avita Medical Limited, a medical device company, develops and distributes regenerative medicine and respiratory products in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The company develops and distributes tissue-engineered products for the treatment of wounds and other skin defects. Its lead product is ReCell, an autologous cell harvesting, processing, and delivery technology that enable surgeons and clinicians to treat skin defects using the patient's own cells in a regenerative process for use in various wound, plastic, reconstructive, burn, and cosmetic procedures. The company also manufactures and sells a range of spacers, including Funhaler incentive asthma spacer for the paediatric market; and Breath-A-Tech spacer for the adolescent and adult markets. Avita Medical Limited is headquartered in Royston, the United Kingdom.

21 Employees
Last Reported Date: 09/26/14

avita medical ltd (AVH) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$328.9K
Vice President of Operations & Quality
Total Annual Compensation: A$153.4K
Vice President of Research & Technology
Total Annual Compensation: A$235.0K
Company Secretary
Total Annual Compensation: A$36.0K
General Manager of Asia Pacific
Total Annual Compensation: A$184.9K
Compensation as of Fiscal Year 2014.

avita medical ltd (AVH) Key Developments

Avita Medical Limited Auditor Raises 'Going Concern' Doubt

Avita Medical Limited filed its Annual on Sep 26, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Avita Medical Limited Secures FDA Approval for US Clinical Trial of ReCell

Avita Medical Limited has secured US Food and Drug Administration (FDA) approval for extensive changes to the US clinical trial of ReCell®, making the trial more accessible to study participants and broadening the scope of use of ReCell to improve market penetration post regulatory approval. After a period of positive dialogue initiated by Avita Medical, the US FDA informed Avita that it has approved, without conditions, the Company's application to broaden the intended clinical indication of ReCell, and to expand patient eligibility. The revised clinical program takes advantage of US clinical experience to date within both the burns trial and FDA-approved compassionate use cases, allowing for evaluation of ReCell as a complementary treatment to expanded meshed skin grafting in a small confirmatory cohort of 25 patients. The major changes to the trial reflect the Company's renewed focus on commercialization efforts.

Avita Medical Limited Reports Preliminary Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Avita Medical Limited reported preliminary audited consolidated earnings results for the year ended June 30, 2014. For the year, the company's sale of goods was $2,683,133 compared to $2,814,990 a year ago. Loss from continuing operations before income tax was AUD 6,659,112 compared to AUD 8,220,993 a year ago. Loss was AUD 5,147,391 compared to AUD 8,092,939 a year ago. Loss is attributable to owners of the company was AUD 5,147,391 compared to AUD 8,092,939 a year ago. Diluted loss per share attributable to ordinary equity holders of the parent was 1.58 cents compared to 2.69 cents a year ago. Net cash flows used in operating activities was AUD 6,924,939 compared to AUD 7,249,403 a year ago. Purchase of plant & equipment was AUD 75,541 compared to AUD 83,596 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVH:AU A$0.09 AUD +0.008

AVH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVH.
View Industry Companies
 

Industry Analysis

AVH

Industry Average

Valuation AVH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVITA MEDICAL LTD, please visit www.avitamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.